Table 1 The prevalence of human herpesvirus 8 (HHV-8) in uterine cervical samples, stratified by several factors
Total | HHV-8 status | p-value | ||
|---|---|---|---|---|
Positive N (%) | Negative N (%) | Total N (%) | ||
62 (17) | 302 (83) | 364 (100) | ||
Samples | ||||
Normal | 26 (14.5) | 153 (85.5) | 179 (100) | |
Premalignant | 22 (17.7) | 102 (82.3) | 124 (100) | 0.308 |
Malignant | 14 (22.9) | 47 (77.1) | 61 (100) | |
Total | 62 (17.0) | 302 (83.0) | 364 (100) | |
Sample types | ||||
FFPE | 18 (15.8) | 96 (84.2) | 114 (100) | |
Thin-prep | 44 (17.6) | 206 (82.4) | 250 (100) | 0.78 |
Total | 62 (17) | 302 (83) | 364 (100) | |
HPV infection | ||||
Positive | 59 (20.3) | 233 (79.7) | 292 (100) | |
Negative | 3 (4.0) | 69 (96.0) | 72 (100) | 0.002 |
Total | 62 (17) | 302 (83) | 364 (100) | |
HPV genotypes | ||||
HPV 16/18 | 19 (15.7) | 102 (84.3) | 121 (100) | |
High-risk HPVs (non-16/18) | 40 (23.4) | 131 (76.6) | 171 (100) | 0.1 |
Total | 59 (20.3) | 233 (79.7) | 292 (100) | |
Cancer types | ||||
SCC | 12 (24.0) | 38 (76.0%) | 50 (100) | |
AC | 2 (18.2) | 9 (81.8) | 11 (100) | 0.98 |
Total | 14 (22.9) | 47 (77.1) | 61 (100) | |
Age group | ||||
20–30 | 7 (11.1) | 52 (88.1) | 59 (100) | |
30–40 | 8 (10.8) | 66 (89.2) | 74 (100) | |
40–50 | 5 (10.7) | 42 (89.3) | 47 (100) | 0.55 |
> 50 | 10 (18.5) | 44 (81.5) | 54 (100) | |
Total | 30 (12.8) | 204 (87.2) | 234 (100) | |